var data={"title":"Epoetin alfa: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Epoetin alfa: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6116?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=epoetin-alfa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Epoetin alfa: Patient drug information&quot;</a> and <a href=\"topic.htm?path=epoetin-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Epoetin alfa: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708743\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular events:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Erythropoiesis-stimulating agents (ESAs) increase the risk of death, MI, stroke, venous thromboembolism, thrombosis of vascular access.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Chronic kidney disease:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered ESAs to target a hemoglobin level of greater than 11 g/dL. No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Use the lowest epoetin alfa dose sufficient to reduce the need for RBC transfusions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cancer:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers. To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions. Use ESAs only for anemia from myelosuppressive chemotherapy. ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure. Discontinue following the completion of a chemotherapy course.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Perisurgery:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Due to increased risk of DVT, DVT prophylaxis is recommended.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165764\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Epogen;</li>\n      <li>Procrit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165765\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Eprex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165808\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Colony Stimulating Factor;</li>\n      <li>\n        Erythropoiesis-Stimulating Agent (ESA);</li>\n      <li>\n        Hematopoietic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165767\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Evaluate iron status in all patients before and during treatment. The manufacturer recommends supplemental iron be administered if serum ferritin is &lt;100 ng/mL or serum transferrin saturation (TSAT) is &lt;20%. Most patients with chronic kidney disease (CKD) will require iron supplementation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>CKD:</b> Individualize dosing and use the lowest dose necessary to reduce the need for RBC transfusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CKD patients </i> <b><i>ON dialysis</i></b> (IV route is preferred for hemodialysis patients; initiate treatment when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 11 g/dL): IV, SubQ: Initial dose: 50 to 100 units/kg 3 times a week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CKD patients </i> <b><i>NOT on dialysis</i></b> (consider initiating treatment when hemoglobin is &lt;10 g/dL; use only if rate of hemoglobin decline would likely result in RBC transfusion and desire is to reduce risk of alloimmunization and/or other RBC transfusion-related risks; reduce dose or interrupt treatment if hemoglobin exceeds 10 g/dL): IV, SubQ: Initial dose: 50 to 100 units/kg 3 times a week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosage adjustments for CKD patients (either on dialysis or not on dialysis):</i> Do not increase dose more frequently than every 4 weeks (dose decreases may occur more frequently); avoid frequent dosage adjustments.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin does not increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period: Reduce dose by &ge;25%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inadequate or lack of response over a 12-week escalation period: Further increases are unlikely to improve response and may increase risks; use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid RBC transfusions and evaluate patient for other causes of anemia. Discontinue therapy if responsiveness does not improve.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Anemia due to chemotherapy in cancer patients:</b> Initiate treatment only if hemoglobin &lt;10 g/dL and anticipated duration of myelosuppressive chemotherapy is at least 2 additional months. Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid RBC transfusions. Discontinue erythropoietin following completion of chemotherapy. SubQ: Initial dose: 150 units/kg 3 times a week or 40,000 units once weekly until completion of chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosage adjustments:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin does not increase by &ge;1 g/dL <b>and</b> remains below 10 g/dL after initial 4 weeks: Increase to 300 units/kg 3 times a week or 60,000 units weekly; discontinue after 8 weeks of treatment if RBC transfusions are still required or there is no hemoglobin response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin exceeds a level needed to avoid RBC transfusion: Withhold dose; resume treatment with a 25% dose reduction when hemoglobin approaches a level where transfusions may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period <b>or</b> hemoglobin reaches a level sufficient to avoid RBC transfusion: Reduce dose by 25%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Anemia due to zidovudine in HIV-infected patients:</b> Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid RBC transfusions. Hemoglobin levels should not exceed 12 g/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum erythropoietin levels &le;500 milliunits/mL and zidovudine doses &le;4,200 mg/week): IV, SubQ: Initial: 100 units/kg 3 times a week; if hemoglobin does not increase after 8 weeks, increase dose by ~50 to 100 units/kg at 4 to 8 week intervals until hemoglobin reaches a level sufficient to avoid RBC transfusion; maximum dose: 300 units/kg. Withhold dose if hemoglobin exceeds 12 g/dL, may resume treatment with a 25% dose reduction once hemoglobin &lt;11 g/dL. Discontinue if hemoglobin increase is not achieved with 300 units/kg for 8 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Reduction of allogeneic RBC transfusion in patients undergoing elective, noncardiac, nonvascular surgery</b> (perioperative hemoglobin should be &gt;10 g/dL and &le;13 g/dL; DVT prophylactic anticoagulation is recommended): SubQ: Initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">300 units/kg/day for 15 days total, beginning 10 days before surgery, on the day of surgery, and for 4 days after surgery <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">600 units/kg once weekly for 4 doses, given 21-, 14-, and 7 days before surgery, and on the day of surgery</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>RBC transfusion refusal (substitute) (off-label use): Note:</b> Concomitantly administer iron (with or without vitamin B<sub>12</sub> and folic acid supplementation) with epoetin alfa and use in conjunction with other blood conservation techniques.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Spinal (elective) surgery:</i> SubQ: 40,000 units weekly for 4 weeks prior to surgery (Joseph 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cardiac (elective) surgery:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">One protocol based on timing of elective surgery and preoperative hemoglobin (Hgb) used the following (McCartney 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;21 days until surgery:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Hgb &lt;10 g/dL:</i> Delay surgery; identify cause of anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Hgb 10 to 12 g/dL:</i> SubQ: 40,000 units (if &lt;65 kg, use 600 units/<b>kg</b>/dose) weekly starting 21 days before surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Hgb &gt;12 to &lt;13 g/dL</i>: SubQ: 40,000 units (if &lt;65 kg, use 600 units/<b>kg</b>/dose) weekly starting 10 days before surgery and repeat 3 days before surgery or on the morning of surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;21 days until surgery:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Hgb &lt;10 g/dL:</i> Delay surgery; identify cause of anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Hgb 10 to 12 g/dL:</i> SubQ: 20,000 units (if &lt;65 kg, use 300 units/<b>kg</b>/dose) daily starting up to 10 days before surgery, on the day of surgery, and 4 days postoperatively if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Hgb &gt;12 to &lt;13 g/dL</i>: SubQ: 20,000 units (if &lt;65 kg, use 300 units/<b>kg</b>/dose) daily starting up to 10 days before surgery, on the day of surgery, and 4 days postoperatively if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Another protocol utilized weight-based dosing (Tanaka 2015):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Preoperative:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 200 units/kg every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">SubQ: 250 to 500 units/kg every 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> Timing prior to surgery was not described; target Hgb of 12 g/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Postoperative:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 200 to 300 units/kg every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">SubQ: 250 to 500 units/kg every 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> Target Hgb &gt;10 g/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Symptomatic anemia in myelodysplastic syndromes (off-label use):</b> SubQ: 150 to 300 units/kg once daily (Greenburg 2009) or 450 to 1000 units/kg/week in divided doses, 3 to 7 times a week (Hellstr&ouml;m-Lindberg 1995) or 60,000 units once weekly (Park 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165789\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=epoetin-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Epoetin alfa: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Evaluate iron status in all patients before and during treatment. The manufacturer recommends supplemental iron be administered if serum ferritin is &lt;100 ng/mL or serum transferrin saturation (TSAT) is &lt;20%. Most patients with chronic kidney disease (CKD) will require iron supplementation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Anemia due to chemotherapy in cancer patients:</b> Initiate treatment only if hemoglobin &lt;10 g/dL and anticipated duration of myelosuppressive chemotherapy is at least 2 additional months. Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid RBC transfusions. Discontinue erythropoietin following completion of chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;5 years of age and Adolescents: IV: Initial dose: 600 units/kg once weekly until completion of chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosage adjustments:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin does not increase by &ge;1 g/dL <b>and</b> remains &lt;10 g/dL after initial 4 weeks: Increase to 900 units/kg (maximum dose: 60,000 units); discontinue after 8 weeks of treatment if RBC transfusions are still required or there is no hemoglobin response.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin exceeds a level needed to avoid RBC transfusion: Withhold dose; resume treatment with a 25% dose reduction when hemoglobin approaches a level where transfusions may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period <b>or</b> hemoglobin reaches a level sufficient to avoid RBC transfusion: Reduce dose by 25%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Anemia due to CKD:</b> Individualize dosing and use the lowest dose necessary to reduce the need for RBC transfusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CKD patients (either on dialysis or not on dialysis) </i>(IV route is preferred for hemodialysis patients; initiate treatment only when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 12 g/dL):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;1 month of age to Adolescents 16 years: IV, SubQ: Initial dose: 50 units/kg 3 times a week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosage adjustments for CKD patients:</i> Do not increase dose more frequently than every 4 weeks (dose decreases may occur more frequently); avoid frequent dosage adjustments</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin does not increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period: Reduce dose by &ge;25%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inadequate or lack of response over a 12-week escalation period: Further increases are unlikely to improve response and may increase risks; use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid RBC transfusions and evaluate patient for other causes of anemia. Discontinue therapy if responsiveness does not improve.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Anemia due to zidovudine in HIV-infected patients:</b> Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid RBC transfusions. Hemoglobin levels should not exceed 12 g/dL. Children 8 months to 17 years (based on limited data): IV, SubQ: Reported dosing range: 50 to 400 units/kg 2 to 3 times a week</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165768\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15822431\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15822432\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165738\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epogen: 10,000 units/mL (2 mL); 20,000 units/mL (1 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Procrit: 10,000 units/mL (2 mL); 20,000 units/mL (1 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epogen: 2000 units/mL (1 mL); 3000 units/mL (1 mL); 4000 units/mL (1 mL); 10,000 units/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Procrit: 2000 units/mL (1 mL); 3000 units/mL (1 mL); 4000 units/mL (1 mL); 10,000 units/mL (1 mL); 40,000 units/mL (1 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165724\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10533184\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Eprex: 1000 units/0.5 mL (0.5 mL), 2000 units/0.5 mL (0.5 mL), 3000 units/0.3 mL (0.3 mL), 4000 units/0.4 mL (0.4 mL), 5000 units/0.5 mL (0.5 mL), 6000 units/0.6 mL (0.6 mL), 8000 units/0.8 mL (0.8 mL), 10,000 units/mL (1 mL), 20,000 units/0.5 mL (0.5 mL), 30,000 units/0.75 mL (0.75 mL), 40,000 units/mL (1 mL) [contains polysorbate 80; prefilled syringe, free of human serum albumin]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874643\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epogen: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5360s5364lbl.pdf#page=58&amp;token=xFJ8BddpD9cyB11fv7QUlWXUSNSYKMnKJnuMCtUf+QkJG8ObiqeL7DMssLDULzlhmzwfQWgsN0pk+QPtbXlyw94yWINU3vy6Zu17MVL7JtKksDlIc53V5oFg97jd6zIL&amp;TOPIC_ID=9410\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5360s5364lbl.pdf#page=58</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Procrit: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM088988.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn//6Xg8g/NxRlbr2OO28Pv6+fgoiCvLQLc6nlvKfQK+AZw==&amp;TOPIC_ID=9410\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM088988.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165742\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: SubQ is the preferred route of administration <b>except</b> in patients with CKD on hemodialysis. In patients with CKD on hemodialysis, the IV route is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Do not shake. Epoetin is usually administered undiluted, although preservative-free (single-dose vial) formulations may be diluted in a syringe prior to administration as a 1:1 dilution using bacteriostatic NS.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165741\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anemia due to chemotherapy in patients with cancer:</b> Treatment of anemia in patients with nonmyeloid malignancies in which anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of 2 additional months of planned chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anemia due to chronic kidney disease:</b> Treatment of anemia due to chronic kidney disease, including patients on dialysis and not on dialysis, to decrease the need for RBC transfusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anemia due to zidovudine in HIV-infected patients:</b> Treatment of anemia due to zidovudine administered at &le;4,200 mg/week in HIV-infected patients with endogenous serum erythropoietin levels of &le;500 milliunits/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reduction of allogeneic RBC transfusion in patients undergoing elective, noncardiac, nonvascular surgery:</b> To reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin &gt;10 to &le;13 g/dL who are at high risk of perioperative blood loss from elective, noncardiac, nonvascular surgery. Epoetin alfa is not indicated for patients who are willing to donate autologous blood preoperatively.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Limitations of use: Epoetin alfa has not been shown to improve quality of life, fatigue, or patient well-being. Epoetin alfa is <b>not</b> indicated for use under the following conditions:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Cancer patients receiving hormonal therapy, therapeutic biologic products, or radiation therapy unless also receiving concurrent myelosuppressive chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Cancer patients receiving myelosuppressive chemotherapy when the expected outcome is curative</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Cancer patients receiving myelosuppressive chemotherapy when anemia can be managed by transfusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Surgery patients who are willing to donate autologous blood</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Surgery patients undergoing cardiac or vascular surgery</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- As a substitute for RBC transfusion in patients requiring immediate correction of anemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725539\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Red blood cell transfusion refusal (substitute); Symptomatic anemia in myelodysplastic syndromes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165818\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epoetin alfa may be confused with darbepoetin alfa, methoxy polyethylene glycol-epoetin beta </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epogen may be confused with Neupogen</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Epopen [Spain] may be confused with EpiPen brand name for epinephrine [US, Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165731\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (6% to 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (5% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (16% to 21%), skin rash (2% to 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (35% to 56%), vomiting (19% to 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site pain (9% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (10% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (4% to 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (10% to 42%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Thrombosis of hemodialysis vascular access (8%), thrombosis (&le;6%), deep vein thrombosis (5% to 6%), edema (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (10%), chills (4% to 7%), insomnia (6%), depression (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Urticaria (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (9%), hyperglycemia (6%), hypokalemia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Stomatitis (10%), dysphagia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Irritation at injection site (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (10%), muscle spasm (7%), ostealgia (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Antibody development (neutralizing), cardiac failure, cerebrovascular accident, erythema, erythema multiforme, hypertensive encephalopathy, myocardial infarction, porphyria, pure red cell aplasia, seizure, severe anemia, skin blisters, skin exfoliation, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165745\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serious allergic reactions to epoetin alfa or any component of the formulation; uncontrolled hypertension; pure red cell aplasia (PRCA) that begins after treatment with epoetin alfa or other epoetin protein drugs; multidose vials contain benzyl alcohol and are contraindicated in neonates, infants, pregnant women, and breastfeeding women</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling</i>: Additional contraindications (not in US labeling): Known hypersensitivity to mammalian cell-derived products or any component of the formulation; patients who for any reason cannot receive adequate antithrombotic treatment; use in patients with severe coronary, peripheral arterial, carotid, or cerebral vascular disease, including patients with recent MI or cerebral vascular accident scheduled for elective surgery and not participating in an autologous blood donation program.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165728\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: <b>[US Boxed Warning]: Erythropoiesis-stimulating agents (ESAs) increased the risk of serious cardiovascular events, MI, stroke, venous thromboembolism, vascular access thrombosis, and mortality in clinical studies when administered to target hemoglobin levels &gt;11 g/dL</b> (and provide no additional benefit); a rapid rise in hemoglobin (&gt;1 g/dL over 2 weeks) may also contribute to these risks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous reactions: Erythema multiforme and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) have been reported with ESA use; discontinue immediately if a severe cutaneous reaction develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Potentially serious allergic reactions have been reported (rarely), including anaphylactic reactions, angioedema, bronchospasm, rash, and urticaria. Discontinue immediately (and permanently) in patients who experience serious allergic/anaphylactic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pure red cell aplasia (PRCA): Cases of severe anemia and PRCA have been reported, predominantly in patients with chronic kidney disease receiving SubQ epoetin alfa (the IV route is preferred for hemodialysis patients); cases have also been reported in patients with hepatitis C who were receiving ESAs, interferon, and ribavirin. Patients with a sudden loss of response (with severe anemia and a low reticulocyte count) should be evaluated for PRCA with associated neutralizing antibodies to erythropoietin; discontinue treatment (permanently) in patients with PRCA secondary to neutralizing antibodies to erythropoietin. Antibodies may cross-react; do not switch to another ESA in patients who develop antibody-mediated anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cancer patients: <b>[US Boxed Warning]: A shortened overall survival and/or increased risk of tumor progression or recurrence has been reported in studies with breast, cervical, head and neck, lymphoid, and non-small cell lung cancer patients.</b> It is of note that in most of in these studies, patients received ESAs to a target hemoglobin of &ge;12 g/dL; although risk has not been excluded when dosed to achieve a target hemoglobin of &lt;12 g/dL. <b>[US Boxed Warnings]: To decrease these risks, and risk of cardio and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusions. Use ESAs in cancer patients only for the treatment of anemia related to concurrent myelosuppressive chemotherapy; discontinue ESA following completion of the chemotherapy course. ESAs are <span style=\"text-decoration: underline\">not</span> indicated for patients receiving myelosuppressive therapy when the anticipated outcome is curative.</b> A dosage modification is appropriate if hemoglobin levels rise &gt;1 g/dL per 2-week time period during treatment (ASCO/ASH [Rizzo 2010]). Use of ESAs has been associated with an increased risk of VTE without a reduction in transfusions in patients &gt;65 years of age with cancer (Hershman 2009). Improved anemia symptoms, quality of life, fatigue, or well-being have not been demonstrated in controlled clinical trials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic kidney disease patients: <b>[US Boxed Warning]: An increased risk of death, serious cardiovascular events, and stroke was reported in chronic kidney disease (CKD) patients administered ESAs to target hemoglobin levels &gt;11 g/dL; use the lowest dose sufficient to reduce the need for RBC transfusions. An optimal target hemoglobin level, dose or dosing strategy to reduce these risks has not been identified in clinical trials.</b> Hemoglobin rising &gt;1 g/dL in a 2-week period may contribute to the risk (dosage reduction recommended). CKD patients who exhibit an inadequate hemoglobin response to ESA therapy may be at a higher risk for cardiovascular events and mortality compared to other patients. ESA therapy may reduce dialysis efficacy (due to increase in red blood cells and decrease in plasma volume); adjustments in dialysis parameters may be needed. Patients treated with epoetin alfa may require increased heparinization during dialysis to prevent clotting of the extracorporeal circuit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Use with caution in patients with a history of hypertension (contraindicated in uncontrolled hypertension). An excessive rate of rise of hemoglobin is associated with hypertension or exacerbation of hypertension; decrease the epoetin alfa dose if the hemoglobin increase exceeds 1 g/dL in any 2-week period. Blood pressure should be controlled prior to start of therapy and monitored closely throughout treatment. Hypertensive encephalopathy has been reported with patients receiving erythropoietic therapy; monitor closely and control blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Perisurgery patients: <b>[US Boxed Warning]: DVT prophylaxis is recommended in perisurgery patients due to the increased risk of DVT. </b> Increased mortality was also observed in patients undergoing coronary artery bypass surgery who received epoetin alfa; these deaths were associated with thrombotic events. Epoetin alfa is <b>not</b> approved for reduction of red blood cell transfusion in patients undergoing cardiac or vascular surgery and is <b>not</b> indicated for surgical patients willing to donate autologous blood.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: The risk for seizures is increased with epoetin alfa use in patients with CKD; use with caution in patients with a history of seizures. Monitor closely for neurologic symptoms during the first several months of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Severe anemia or acute blood loss: Due to the delayed onset of erythropoiesis, epoetin alfa is not recommended for acute correction of severe anemia or as a substitute for emergency transfusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage form specific issues:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Product may contain albumin, which confers a theoretical risk of transmission of viral disease or Creutzfeldt-Jakob disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Oncology: The American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) 2010 updates to the clinical practice guidelines for the use of ESAs in patients with cancer indicate that ESAs are appropriate when used according to the parameters identified within the FDA approved labeling for epoetin and darbepoetin alfa (ASCO/ASH [Rizzo 2010]). ESAs are an option for chemotherapy associated anemia when the hemoglobin has fallen to &lt;10 g/dL to decrease the need for RBC transfusions. ESAs should only be used in conjunction with concurrent chemotherapy. Although the FDA label now limits ESA use to the palliative setting, the ASCO/ASH guidelines suggest using clinical judgment in weighing risks versus benefits as formal outcomes studies of ESA use defined by intent of chemotherapy treatment have not been conducted.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Cardiovascular disease: The American College of Physicians recommends against the use of ESAs in patients with mild to moderate anemia and heart failure or coronary heart disease (ACP [Qaseem 2013]). The ACCF/AHA 2013 Heart Failure Guidelines do not provide a clear recommendation on the use of ESAs in anemic heart failure patients. The effects of ESAs on quality of life measures, morbidity, and mortality are potentially modest and still unclear. Additionally, the safety of epoetin alfa has not been well studied in this population. The authors declined to provide an official recommendation regarding the use of ESAs pending the completion of ongoing randomized trials (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Factors impairing erythropoiesis: Prior to treatment, correct or exclude deficiencies of iron, vitamin B<sub>12</sub>, and/or folate, as well as other factors which may impair erythropoiesis (inflammatory conditions, infections, bleeding). Poor response to therapy should prompt evaluation of potential factors impairing erythropoiesis, as well as possible malignant processes and hematologic disease (thalassemia, refractory anemia, myelodysplastic disorder), occult blood loss, hemolysis, osteitis fibrosa cystic, and/or bone marrow fibrosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299274\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220130\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9410&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Lenalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nandrolone: May enhance the stimulatory effect of Erythropoiesis-Stimulating Agents. Specifically, nandrolone may enhance the erythropoiesis stimulatory effect of Erythropoiesis-Stimulating Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165734\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165749\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. In vitro studies suggest that recombinant erythropoietin does not cross the human placenta (Reisenberger 1997). Polyhydramnios and intrauterine growth retardation have been reported with use in women with chronic kidney disease (adverse effects also associated with maternal disease). Hypospadias and pectus excavatum have been reported with first trimester exposure (case report).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Recombinant erythropoietin alfa has been evaluated as adjunctive treatment for severe pregnancy associated iron deficiency anemia (Breymann 2001; Krafft 2009) and has been used in pregnant women with iron-deficiency anemia associated with chronic kidney disease (CKD) (Furaz-Czerpak 2012; Josephson 2007).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Amenorrheic premenopausal women should be cautioned that menstruation may resume following treatment with recombinant erythropoietin (Furaz-Czerpak 2012). Multidose formulations containing benzyl alcohol are contraindicated for use in pregnant women; if treatment during pregnancy is needed, single dose preparations should be used.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women who become pregnant during treatment with epoetin alfa are encouraged to enroll in Amgen&rsquo;s Pregnancy Surveillance Program (1-800-772-6436).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165750\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Endogenous erythropoietin is found in breast milk (Semba 2002). It is not known if recombinant erythropoietin alfa is present in breast milk. The manufacturer recommends caution be used if the single dose vial preparation is administered to breastfeeding women; use of the multiple dose vials containing benzyl alcohol is contraindicated in breastfeeding women. When administered enterally to neonates (mixed with human milk or infant formula), recombinant erythropoietin did not significantly increase serum EPO concentrations. If passage via breast milk does occur, risk to a breastfed infant appears low (Juul 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165736\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Transferrin saturation and serum ferritin (prior to and during treatment); hemoglobin (weekly after initiation and following dose adjustments until stable and sufficient to minimize need for RBC transfusion, CKD patients should be also be monitored at least monthly following hemoglobin stability); blood pressure; monitor for signs of seizures (CKD patients following initiation for first few months, includes new-onset or change in seizure frequency or premonitory symptoms).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Cancer patients: Examinations recommended by the ASCO/ASH guidelines (Rizzo 2010) prior to treatment include: peripheral blood smear (in some situations a bone marrow exam may be necessary), assessment for iron, folate, or vitamin B<sub>12</sub> deficiency, reticulocyte count, renal function status, and occult blood loss; during ESA treatment, assess baseline and periodic iron, total iron-binding capacity, and transferrin saturation or ferritin levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165739\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Zidovudine-treated HIV patients: Available evidence indicates patients with endogenous serum erythropoietin levels &gt;500 mU/mL are unlikely to respond </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165727\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Epoetin alfa induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells; induces the release of reticulocytes from the bone marrow into the bloodstream, where they mature to erythrocytes. There is a dose response relationship with this effect. This results in an increase in reticulocyte counts followed by a rise in hematocrit and hemoglobin levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165744\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> While a much higher peak plasma concentration is achieved after IV bolus administration, it declines at a more rapid rate than after subcutaneous administration (McMahon 1990; Salmonson 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Reticulocyte count increase: Within 10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Hemoglobin level: 2 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: SubQ: Slow (McMahon 1990; Salmonson 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 9 L; rapid in the plasma compartment; concentrated in liver, kidneys, and bone marrow; similar to extracellular plasma volume in adults (McMahon 1990; Salmonson 1990); reported to be higher in premature neonates on body weight basis (Brown 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Some degradation does occur</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: Premature neonates: 42% (Brown 1993); Adults: 36% (Salmonson 1990); intraperitoneal epoetin alfa: 3% (Macdougall 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: With high doses, nonlinear kinetics have been observed (Wu 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Anemia of prematurity:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Post menstrual age (PMA) &lt;32 week (weight: 800 &plusmn; 206 grams): IV: 8.1 &plusmn; 2.7 hours; SubQ: 7.1 &plusmn; 4.1 hours (Brown 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PMA &ge;32 weeks (weight range: 1,330 to 1,740 g): SubQ: Median: 7.9 hours (range: 5.6 to 19.4 hours) (Krishnan 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuroprotective/hypoxic ischemia encephalopathy (HIE) (Wu 2012): &ge;36 weeks GA; IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">250 units/kg: 7.6 &plusmn; 6.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">500 units/kg: 7.2 &plusmn; 1.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">1,000 units/kg: 15 &plusmn; 4.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">2,500 units/kg: 18.7 &plusmn; 4.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: Chronic kidney disease: IV: 4 to 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Cancer: SubQ: 16 to 67 hours; Chronic kidney disease: IV: 4 to 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Pediatric patients &gt;1 month and Adults: Chronic kidney disease: SubQ: 5 to 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165748\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Epogen Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 units/mL (1 mL): $39.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 units/mL (1 mL): $59.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000 units/mL (1 mL): $79.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 units/mL (1 mL): $198.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000 units/mL (1 mL): $397.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Procrit Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 units/mL (1 mL): $61.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 units/mL (1 mL): $92.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000 units/mL (1 mL): $123.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 units/mL (1 mL): $308.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000 units/mL (1 mL): $617.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40000 units/mL (1 mL): $1,234.63</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165751\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abseamed (TR);</li>\n      <li>Binocrit (CH, ES, GB, HR, IE, IL, JO, MT, MY, RO, TR);</li>\n      <li>Efotin (PH);</li>\n      <li>EPIAO (TH);</li>\n      <li>Epodion (ID);</li>\n      <li>Epogen (PH);</li>\n      <li>Epokine (PH);</li>\n      <li>Eporon (TH);</li>\n      <li>Eposino (PH);</li>\n      <li>Eposis (KR, PH, TH);</li>\n      <li>Epotin (AE, KW, LB, QA);</li>\n      <li>Epovax (PH);</li>\n      <li>Eprex (AE, AR, AU, BB, BD, BE, BG, BH, BM, BR, BS, BZ, CH, CR, CY, CZ, DK, DO, EE, EG, ES, FI, FR, GB, GR, GT, GY, HK, HN, HR, HU, IE, IN, IQ, IR, IT, JM, JO, KW, LB, LK, LU, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PY, QA, RO, RU, SA, SE, SG, SR, SV, SY, TH, TR, TT, TW, UY, VE, VN, YE);</li>\n      <li>Erykine (TZ);</li>\n      <li>Erypo (AT, DE);</li>\n      <li>Espo (CN, JP);</li>\n      <li>Espogen (TH);</li>\n      <li>Hemapo (TH, VN);</li>\n      <li>Hemax (TH);</li>\n      <li>Hypercrit (BR, CL);</li>\n      <li>Renogen (PH, TH);</li>\n      <li>Repoitin 4000 (PH);</li>\n      <li>Yi Pu Li (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ball AM, Winstead PS. Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses. <i>Pharmacotherapy</i>. 2008;28(11):1383-1390. doi:10.1592/phco.28.11.1383.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/18956998/pubmed\" target=\"_blank\" id=\"18956998\">18956998</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bennett CL, Cournoyer D, Carson KR, et al, &quot;Long-Term Outcome of Individuals With Pure Red Cell Aplasia and Antierythropoietin Antibodies in Patients Treated With Recombinant Epoetin: A Follow-up Report From the Research on Adverse Drug Events and Reports (RADAR) Project,&quot;<i>Blood</i>, 2005, 106(10):3343-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/16099877/pubmed\" target=\"_blank\" id=\"16099877\">16099877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bennett CL, Silver SM, Djulbegovic B, et al, &ldquo;Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia,&rdquo; <i>JAMA</i>, 2008, 299(8):914-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/18314434/pubmed\" target=\"_blank\" id=\"18314434\">18314434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Breymann C, Visca E, Huch R, et al, &quot;Efficacy and Safety of Intravenously Administered Iron Sucrose With and Without Adjuvant Recombinant Human Erythropoietin for the Treatment of Resistant Iron-Deficiency Anemia During Pregnancy,&quot; <i>Am J Obstet Gynecol</i>, 2001, 184(4):662-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/11262469/pubmed\" target=\"_blank\" id=\"11262469\">11262469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown MS, Eichorst D, Lala-Black B, Gonzalez R. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants. <i>Pediatrics</i>. 2009;124(4):e681-687. doi:10.1542/peds.2008-2701<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/19786428/pubmed\" target=\"_blank\" id=\"19786428\">19786428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brunetta DM, Kaufman J, De Santis GC, et al. Severe Acute Anemia After Liver Transplantation in an Elderly Jehovah's Witness Treated With High-dose Erythropoietin and Ferric Carboxymaltose: A Case Report. <i>Transplant Proc</i>. 2015 Oct;47(8):2548-51. doi:10.1016/j.transproceed.2015.09.014.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/26518969/pubmed\" target=\"_blank\" id=\"26518969\">26518969</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, Berkovits E, Goldman WM. Room-temperature storage of medications labeled for refrigeration. <i>Am J Health Syst Pharm</i>. 2007;64(16):1711-1715.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corbo DC, Suddith RL, Sharma B, Naso RB. Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacteriostatic diluent. <i>Am J Hosp Pharm</i>. 1992;49(6):1455-1458.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/1529989/pubmed\" target=\"_blank\" id=\"1529989\">1529989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corwin HL, Gettinger A, Fabian TC, et al, &quot;Efficacy and Safety of Epoetin Alfa in Critically Ill Patients,&quot; <i>N Engl J Med</i>, 2007, 357(10):965-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/17804841/pubmed\" target=\"_blank\" id=\"17804841\">17804841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corwin HL, Gettinger A, Pearl RG, et al, &ldquo;Efficacy of Recombinant Human Erythropoietin in Critically Ill Patients: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2002, 288(22):2827-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/12472324/pubmed\" target=\"_blank\" id=\"12472324\">12472324</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cournoyer D, Toffelmire EB, Wells GA, et al, &quot;Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia After Treatment With Recombinant Erythropoietin Products: Recommendations for Minimization of Risk,&quot; <i>J Am Soc Nephrol</i>, 2004, 15(10):2728-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/15466278/pubmed\" target=\"_blank\" id=\"15466278\">15466278</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dallas T, Welsby I, Bottiger B, Milano C, Daneshmand M, Guinn N. Bloodless Orthotopic Heart Transplantation in a Jehovah's Witness. <i>A A Case Rep</i>. 2015;4(10):140-142. doi:10.1213/XAA.0000000000000067.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/25974419/pubmed\" target=\"_blank\" id=\"25974419\">25974419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo; <i>Crit Care Med</i>, 2013, 41(2):580-637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/23353941/pubmed\" target=\"_blank\" id=\"23353941\">23353941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drueke TB, Locatelli F, Clyne N, et al, &ldquo;Normalization of Hemoglobin Level in Patients With Chronic Kidney Disease and Anemia,&rdquo; <i>N Engl J Med</i>, 2006, 355(20): 2071-84.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Epogen (epoetin alfa) [prescribing information]. Thousand oaks, CA: Amgen; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eprex (epoetin alfa) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fenaux P, Haase D, Sanz GF, Santini V, Buske C; ESMO Guidelines Working Group. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2014;25 Suppl 3:iii57-iii69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/25185242/pubmed\" target=\"_blank\" id=\"25185242\">25185242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feusner J and Hastings C, &ldquo;Recombinant Human Erythropoietin in Pediatric Oncology: A Review,&rdquo; <i>Med Pediatr Oncol</i>, 2002, 39(4):463-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/12203665/pubmed\" target=\"_blank\" id=\"12203665\">12203665</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furaz-Czerpak KR, Fern&aacute;ndez-Ju&aacute;rez G, Moreno-de la Higuera M&Aacute;, et al, &quot;Pregnancy in Women on Chronic Dialysis: A Review,&quot; <i>Nefrologia</i>, 2012, 32(3):287-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/22508145/pubmed\" target=\"_blank\" id=\"22508145\">22508145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19564636\"></a>Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). <i>Blood</i>. 2009;114(12):2393-2400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/19564636/pubmed\" target=\"_blank\" id=\"19564636\">19564636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hebert PC, Wells G, Blajchman MA, et al, &ldquo;A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group,&rdquo; <i>N Engl J Med</i>, 1999, 340(6):409-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/9971864/pubmed\" target=\"_blank\" id=\"9971864\">9971864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7833279\"></a>Hellstr&ouml;m-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. <i>Br J Haematol</i>. 1995;89(1):67-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/7833279/pubmed\" target=\"_blank\" id=\"7833279\">7833279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. <i>J Natl Cancer Inst</i>. 2009;101(23):1633-1641. doi:10.1093/jnci/djp387.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/19903808/pubmed\" target=\"_blank\" id=\"19903808\">19903808</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joosten E, Van Hove L, Lesaffre E, et al, &ldquo;Serum Erythropoietin Levels in Elderly Inpatients With Anemia of Chronic Disorders and Iron Deficiency Anemia,&rdquo; <i>J Am Geriatr Soc</i>, 1993, 41(12):1301-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/8227911/pubmed\" target=\"_blank\" id=\"8227911\">8227911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joseph SA Jr, Berekashvili K, Mariller MM, et al. Blood conservation techniques in spinal deformity surgery: a retrospective review of patients refusing blood transfusion. <i>Spine (Phila Pa 1976)</i>. 2008;33(21):2310-2315. doi:10.1097/BRS.0b013e31818047f2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/18827697/pubmed\" target=\"_blank\" id=\"18827697\">18827697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Josephson MA and McKay DB, &quot;Considerations in the Medical Management of Pregnancy in Transplant Recipients, <i>Adv Chronic Kidney Dis</i>, 2007, 14(2):156-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/17395118/pubmed\" target=\"_blank\" id=\"17395118\">17395118</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juul SE and Christensen RD, &ldquo;Absorption of Enteral Recombinant Human Erythropoietin By Neonates,&rdquo; <i>Ann Pharmacother</i>, 2003, 37(6):782-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/12773061/pubmed\" target=\"_blank\" id=\"12773061\">12773061</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kharagjitsingh AV, Korevaar JC, Vandenbroucke JP, et al, &quot;Incidence of Recombinant Erythropoietin (EPO) Hyporesponse, EPO-Associated Antibodies, and Pure Red Cell Aplasia in Dialysis Patients,&quot; <i>Kidney Int</i>, 2005, 68(3):1215-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/16105053/pubmed\" target=\"_blank\" id=\"16105053\">16105053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krafft A, Bencaiova G, and Breymann C, &quot;Selective Use of Recombinant Human Erythropoietin in Pregnant Patients With Severe Anemia or Nonresponsive to Iron Sucrose Alone,&quot; <i>Fetal Diagn Ther</i>, 2009, 25(2):239-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/19506383/pubmed\" target=\"_blank\" id=\"19506383\">19506383</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krishnan R, Shankaran S, Krishnan M, Kauffman RE, Kumar P, Lucena J. Pharmacokinetics of erythropoietin following single-dose subcutaneous administration in preterm infants. <i>Biol Neonate</i>. 1996;70(3):135-140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/8894079/pubmed\" target=\"_blank\" id=\"8894079\">8894079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. <i>Lancet</i>. 1989;1(8635):425-427.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/2563798 /pubmed\" target=\"_blank\" id=\"2563798 \">2563798 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malcovati L, Hellstr&ouml;m-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <i>Blood</i>. 2013;122(17):2943-2964.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/23980065/pubmed\" target=\"_blank\" id=\"23980065\">23980065</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCartney S, Guinn N, Roberson R, et al. Jehovah's Witnesses and cardiac surgery: a single institution's experience. <i>Transfusion</i>. 2014;54(10 Pt 2):2745-2752. doi:10.1111/trf.12696.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/24809815/pubmed\" target=\"_blank\" id=\"24809815\">24809815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injection in healthy volunteers. <i>Blood</i>. 1990;76(9):1718-1722.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/2224121/pubmed\" target=\"_blank\" id=\"2224121\">2224121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nafziger J, Pailla K, Luciani L, et al, &ldquo;Decreased Erythropoietin Responsiveness to Iron Deficiency Anemia in the Elderly,&rdquo; <i>Am J Hematol</i>, 1993, 43(3):172-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/8352231/pubmed\" target=\"_blank\" id=\"8352231\">8352231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Napolitano LM, Fabian TC, Kelly KM, et al, &quot;Improved Survival of Critically Ill Trauma Patients Treated With Recombinant Human Erythropoietin,&quot; <i>J Trauma</i>, 2008, 65(2):285-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/18695463/pubmed\" target=\"_blank\" id=\"18695463\">18695463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation, &ldquo;KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease,&rdquo; Am J Kidney Dis, 2007, 50(3):529-30. Available at http://www2.kidney.org/professionals/KDOQI/guidelines_anemiaUP/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naughton CA, Duppong LM, Forbes KD, Sehgal I. Stability of multidose, preserved formulation epoetin alfa in syringes for three and six weeks. <i>Am J Health Syst Pharm</i>. 2003;60(5):464-468.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/12635452/pubmed\" target=\"_blank\" id=\"12635452\">12635452</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohls RK, Christensen RD. Stability of human recombinant epoetin alfa in commonly used neonatal intravenous solutions. <i>Ann Pharmacother</i>. 1996;30(5):466-468.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/8740324/pubmed\" target=\"_blank\" id=\"8740324\">8740324</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17940203\"></a>Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. <i>Blood</i>. 2008;111(2):574-582.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/17940203/pubmed\" target=\"_blank\" id=\"17940203\">17940203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phronmmintikul A, Haas SJ, Elsik M, et al, &ldquo;Mortality and Target Haemoglobin Concentrations in Anaemic Patients with Chronic Kidney Disease Treated With Erythropoietin: A Meta-Analysis, <i>Lancet</i>, 2007, 369(9559):381-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/17276778/pubmed\" target=\"_blank\" id=\"17276778\">17276778</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plunkett H, Gass H, Gross R. Intraoperative Blood Loss Among Jehovah's Witnesses in Spinal Deformity Surgery: A Report of 5 Cases. <i>J S C Med Assoc</i>. 2015;111(2):59-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/27132333/pubmed\" target=\"_blank\" id=\"27132333\">27132333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Procrit [package insert]. Raritan, NJ: Centocor Ortho Biotech Products LP; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Procrit (epoetin alfa) [prescribing information]. Horsham, PA: Janssen; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qaseem A, Humphrey LL, Fitterman N, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Treatment of anemia in patients with heart disease: a clinical practice guideline from the american college of physicians. <i>Ann Intern Med</i>. 2013;159(11):770-779.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/24297193/pubmed\" target=\"_blank\" id=\"24297193\">24297193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rebel A, Beck A, Efron P, Bavry AA, Ang D. Successful Rescue Therapy for Severe Acute Anemia: Managing the Critically Ill Jehovah's Witness. <i>Am Surg</i>. 2015;81(6):E263-265.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/26031262/pubmed\" target=\"_blank\" id=\"26031262\">26031262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reisenberger K, Egarter C, Kapiotis S, et al, &quot;Transfer of Erythropoietin Across the Placenta Perfused <i>in vitro</i>,&quot; <i>Obstet Gynecol</i>, 1997, 89(5 Pt 1):738-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/9166312/pubmed\" target=\"_blank\" id=\"9166312\">9166312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzo JD, Brouwers M, Hurley P, et al; American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. <i>J Clin Oncol</i>. 2010;28(33):4996-5010. doi:10.1200/JCO.2010.29.2201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/20975064/pubmed\" target=\"_blank\" id=\"20975064\">20975064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzo JD, Somerfield MR, Hagerty LK, et al, &ldquo;American Society of Hematology/American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin,&rdquo; <i>Blood</i>, 2008, 111(1):25-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/17954703/pubmed\" target=\"_blank\" id=\"17954703\">17954703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salmonson T, Danielson BG, and Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. <i>Br J Clin Pharmac</i>. 1990; 29:709-713.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/2378790/pubmed\" target=\"_blank\" id=\"2378790\">2378790</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Semba RD and Juul SE, &quot;Erythropoietin in Human Milk: Physiology and Role in Infant Health,&quot; <i>J Hum Lact</i>, 2002, 18(3):252-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/12192960/pubmed\" target=\"_blank\" id=\"12192960\">12192960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh AJ, Szczech L, Tang Kl, et al, &ldquo;Correction of Anemia With Epoetin Alfa in Chronic Kidney Disease,&rdquo; <i>N Engl J Med</i>, 2006, 355(20):2085-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/17108343/pubmed\" target=\"_blank\" id=\"17108343\">17108343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Society of Thoracic Surgeons Blood Conservation Guideline Task Force and Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion, &ldquo;Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline,&rdquo; <i>Ann Thorac Surg</i>, 2007, 83(5 Suppl):27-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/17462454/pubmed\" target=\"_blank\" id=\"17462454\">17462454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Society of Thoracic Surgeons Blood Conservation Guideline Task Force. Ferraris VA, Brown JR, Despotis GJ, et al.; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion. Shore-Lesserson LJ, Goodnough LT, Mazer CD, et al.; International Consortium for Evidence Based Perfusion. Baker RA, Dickinson TA, FitzGerald DJ, Likosky DS, Shann KG. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. <i>Ann Thorac Surg</i>. 2011;91(3):944-982. doi:10.1016/j.athoracsur.2010.11.078.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/1353044/pubmed\" target=\"_blank\" id=\"1353044\">1353044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Swedberg K, Young JB, Anand IS, et al; RED-HF Committees; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. <i>N Engl J Med</i>. 2013;368(13):1210-1219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/23473338/pubmed\" target=\"_blank\" id=\"23473338\">23473338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tanaka A, Ota T, Uriel N, et al. Cardiovascular surgery in Jehovah's Witness patients: The role of preoperative optimization. <i>J Thorac Cardiovasc Surg</i>. 2015;150(4):976-983.e1-3. doi:10.1016/j.jtcvs.2015.06.059.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/26211405/pubmed\" target=\"_blank\" id=\"26211405\">26211405</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teehan G and Benz RL, &ldquo;An Update on the Controversies in Anemia Management in Chronic Kidney Disease: Lessons Learned and Lost,&rdquo; <i>Anemia</i>, 2011, 2011:623673.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/21541213/pubmed\" target=\"_blank\" id=\"21541213\">21541213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinthal JA, &ldquo;The Role of Cytokines Following Bone Marrow Transplantation: Indications and Controversies,&rdquo; <i>Bone Marrow Transplant</i>, 1996, 18(Suppl 3):10-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wu YW, Bauer LA, Ballard RA, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. <i>Pediatrics</i>. 2012;130(4):683-691. doi:10.1542/peds.2012-0498.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/23008465/pubmed\" target=\"_blank\" id=\"23008465\">23008465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9410 Version 169.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708743\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F165764\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F165765\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F165808\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F165767\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F165789\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F165768\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15822431\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15822432\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F165738\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F165724\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10533184\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874643\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F165742\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F165741\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725539\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F165818\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F165731\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F165745\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F165728\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299274\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220130\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F165734\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F165749\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F165750\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F165736\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F165739\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F165727\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F165744\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F165748\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F165751\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9410|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=epoetin-alfa-patient-drug-information\" class=\"drug drug_patient\">Epoetin alfa: Patient drug information</a></li><li><a href=\"topic.htm?path=epoetin-alfa-pediatric-drug-information\" class=\"drug drug_pediatric\">Epoetin alfa: Pediatric drug information</a></li></ul></div></div>","javascript":null}